Clinical trial NCT01850342: Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence
Official title: Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence Via Endoscopically-Assisted Administration of Fat Tissue Micrografts Enriched by Autologous Adipose-Derived Regenerative Cells
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Stress Urinary Incontinence
Keywords: Male stress urinary incontinence
Cell-assisted lipotransfer
Adipose-derived regenerative cells
ADRC
Micrograft
Fat tissue
Stem cells
Lead sponsor: Burnasyan Federal Medical Biophysical Center
Sponsor class: OTHER_GOV
First posted: 2013-05-09
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Autologous washed and homogenized fat micrograft harvested from the patient's front abdominal wall enriched with adipose-derived regenerative cells (ADRC) derived by enzyme-treatment of a portion of the harvested fat. Fat tissue micrograft mixed with ADRC will be administered one-time endoscopically into submucosal layer of urethra under eye control. This is a single arm study with no control. All patients receive cell therapy.

Detailed description: Fat tissue obtainment. Subjects will undergo liposuction under local anesthesia. In this procedure, Ringer's solution with the anesthetic lidocaine and vasoconstrictor adrenaline infused into the adipose compartment to minimize blood loss and contamination of the tissue by peripheral blood cells. 15 minutes later a hollow blunt-tipped 3 mm cannula introduced into the subcutaneous space through small (0.5 cm) incision. The cannula attached to syringe and under gentle suction moved through the adipose compartment, mechanically disrupting the fat tissue. Aspirate volume - approximately 150 cc. Procedure time - 30 minutes.

ADRC isolation. Aspirated fat tissue placed into sterile tubes with transport medium and delivered into the laboratory within 15 minutes. To isolate the ADRC, part of lipoaspirate (approximately 100 cc) washed extensively with equal volumes of phosphate-buffered saline and digested with collagenase. After enzyme activity neutralization decomposed fat tissue eliminated and ADRC washed 3 times with saline. Cells divided into 3 portions. First portion used for counting, viability and sterility assessment. Second portion prepared for freezing in liquid nitrogen. Third portion mixed with fat micrograft.

Fat tissue enriched micrograft preparation. Obtained fat tissue (approximately 20-30 cc) washed repeatedly. Aspirated fat settled down in syringes placed in vertical position, after that liquid fraction eliminated. Syringes with fat filled up with Ringer's solution and procedure of settlement repeated 3-5 times. Washed fat placed on metallic mesh and mashed up using metallic spatula. Homogenized fat mixed with prepared ADRC and collected in syringe for further injection. Ratio fat micrograft/fat for ADRC estimated according to aspirate volume and usually forms 1:10. For example, ADRC obtained from 100 cc of fat tissue should be mixed with 10 cc of fat micrograft.

Fat micrograft preparation is also possible in Puregraft System (Cytori Therapeutics Inc) - closed disposable system for fat tissue selective washing.

Periurethral injection of fat micrograft enriched with ADRC Urethra punctured several times circle-wise at the bulbomembranous region at a depth of 5 mm under endoscopic vision and 0.5-1 mL of fat micrograft enriched with ADRC injected each time. Total volume of solution injected - approximately 8 mL. After fat micrograft injected, urethral balloon catheter placed and removed the following day.

Eligibility criteria: Inclusion Criteria:

* Patient suffers from stress urinary incontinence due to insufficiency of the urethral sphincter at least for 2 years.
* Moderate and severe grade of urinary incontinence according to assessment made by investigator.
* Patient is familiar with Participant information sheet.
* Patient signed informed consent form.

Exclusion Criteria:

* Contraindications for local anesthesia.

For the patients undergone surgical treatment of prostate cancer:

* Cancer relapse.
* prostate-specific antigen (PSA) level \>0.008 ng/mL.

Primary outcomes:
measure: Safety endpoints
timeFrame: 4 weeks after treatment
Secondary outcomes:
measure: Efficacy endpoints
timeFrame: 2, 4, 8, 12, 16, 24 weeks after treatment
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: State Research Center Burnasyan Federal Medical Biophysical Center FMBA of Russia; Center for Biomedical Technologies
Study officials:
affiliation: Burnasyan Federal Medical Biophysical Center
name: Ilya I Eremin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Burnasyan Federal Medical Biophysical Center
name: Pavel S Kyzlasov, MD
role: PRINCIPAL_INVESTIGATOR
References: